Xcout Intel
PHILOGEN competitors & alternatives
The 12 closest competitors and alternatives to PHILOGEN among biotech companies — ranked by similarity to what PHILOGEN actually does, not by market-cap band.
Subscribe to see PHILOGEN’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About PHILOGEN
Philogen is a Swiss-Italian biotechnology company that focuses on the research, development, and commercialization of targeted therapeutics for the treatment of cancer and other serious conditions. The company utilizes proprietary antibody-based technologies to develop biopharmaceuticals, immunotherapies, and radio-conjugates for oncology and imaging applications.
PHILOGEN at a glance
PHILOGEN is a biotech company headquartered in Italy. Xcout tracks 19 named people at PHILOGEN, including Henry D. Fahman (Chairman, Chief Executive Officer, President & Acting Chief Financial Officer).
PHILOGEN leadership
- Henry D. FahmanChairman, Chief Executive Officer, President & Acting Chief Financial Officer
- Frank StankunasPresident, Secretary & Director - Cornerstone Biomass Corp
- Horace HorumbaPresident of Eastern Europe
- Venkateswar Rao GopisettiPresident of PHIVITAE Healthcare, Inc. & MD of PHI Vietnam Investment & Development Ltd.
- Dario NeriChief Executive Officer & Chief Scientific Officer Co-founder
- Giovanni NeriHead of Licensing & IP Co-founder
13 more named people on record for PHILOGEN, with roles, board committees and tenure — see the full roster →
Top 12 PHILOGEN competitors
Ranked by semantic similarity — how close each company is to PHILOGEN by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotechnology
Pheon Therapeutics is a biotechnology research company headquartered in London, England, that specializes in developing next-generation antibody-drug conjugates for hard-to-treat cancers.
Biotechnology
Curon Biopharmaceutical is a clinical-stage biotechnology company developing antibody-based medicines, including bispecific antibodies, for cancer and other serious diseases. It serves patients and healthcare providers through the development of therapeutic biologics, with programs intended for oncology and immunology applications.
Biotechnology
T3 Pharmaceuticals AG is a biotechnology company that develops a proprietary technology platform utilizing bacteria to deliver targeted therapies. The company focuses on advancing a pipeline of Immuno-Oncology products designed to treat cancer patients.
Biotechnology
ImmunOs Therapeutics AG is a biotechnology company that develops treatments for cancer and inflammatory diseases by harnessing the human immune system. The company focuses on immuno-oncology and autoimmune therapies through a dedicated drug pipeline.
Biotechnology
Theragene Pharmaceuticals, Inc. is a privately held biopharmaceutical company headquartered in Los Angeles, California, focusing on immunotherapy technologies.
Similar biotech company
Numab Therapeutics is a Swiss biotechnology company developing multispecific antibody-based medicines that modulate immune-cell interactions. Its programs target serious diseases including cancer and immune-mediated or inflammatory disorders, serving patients through development and potential partnerships with pharmaceutical companies.
Biotechnology
VAXIMM AG is a biotech company headquartered in Basel, Switzerland, that focuses on developing a new class of cytotoxic immunotherapies and clinical-stage targeted treatments through its subsidiaries.
Biotechnology
Anaveon is a late-stage preclinical biotechnology company based in Basel, Switzerland, focused on developing engineered antibodies for immunotherapy.
Biotechnology
NBE-Therapeutics is a biotechnology company founded in 2012 and headquartered in Basel, Switzerland, focused on developing antibody-drug conjugates for oncology treatments.
Similar biotech company
Polpharma Biologics is a biotechnology company that develops and manufactures biosimilar medicines to improve patient access to biopharmaceuticals. Operating from Switzerland, the company manages a broad portfolio of biosimilars targeting major therapeutic areas and collaborates with global biopharmaceutical partners to bring these treatments from concept to commercial supply.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of PHILOGEN and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for PHILOGENand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →